Enhanced Antitumor Efficacy of Novel Biomimetic Platelet Membrane-Coated Tetrandrine Nanoparticles in Nonsmall Cell Lung Cancer-Reference-Cited by-全球学者库

Enhanced Antitumor Efficacy of Novel Biomimetic Platelet Membrane-Coated Tetrandrine Nanoparticles in Nonsmall Cell Lung Cancer

Published:2023-10-12 Issue:11 Volume:20 Page:5463-5475
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Jiang Hui¹²,Tang Chunming²,Wen Yuanyuan¹^ORCID,Zhao Qianqian²,Xu Mingyuan³,Fan Jinting²,Wang Zhiji²,Wang Lifeng³,Xu Huae¹²^ORCID,Chen Gang⁴

Affiliation:

1. Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210009, China

2. Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

3. The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University Medical School, Nanjing 210093, China

4. General Surgery Department, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210000, China

Funder

Nanjing Medical University

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00310

Reference44 articles.

1. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

2. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

3. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

4. MEK inhibitors for the treatment of non-small cell lung cancer

5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial